Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05565742 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 320
- Enrollment target
NCT05565742 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 320 participants.
The verdict
NCT05565742, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 320 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.
Interventions
- DRUG Placebo
- DRUG LY3819469
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2022-10-20 |
| Est. Completion | 2024-10-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05565742
The ClinicalTrials.gov registry entry for NCT05565742 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05565742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05565742 about?
NCT05565742 is a clinical study titled "A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]". The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.
What is the current status of trial NCT05565742?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2022-10-20. Estimated completion is 2024-10-17.
What interventions are being tested in trial NCT05565742?
The interventions under investigation include: Placebo (DRUG), LY3819469 (DRUG).
Who is sponsoring clinical trial NCT05565742?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.